project id: TCGA-PRAD; case submitter id: TCGA-XK-AAJT; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.07; rna integrity number: 8.1; age at index: 75; days to birth: -27428; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1935; age at diagnosis: 27428; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1434.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1135; days to sample procurement: 0; initial weight: 10.0; sample id: 4791634b-bcd4-4fda-abdb-dec79ba05086; sample submitter id: TCGA-XK-AAJT-01A; portion id: 58a520fd-36ac-45f9-a34d-972c334241a0; portion submitter id: TCGA-XK-AAJT-01A-11; slide id: 0ade397e-a876-4d29-87dd-3b203cc00136; slide submitter id: TCGA-XK-AAJT-01Z-00-DX1; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 1.0; percent neutrophil infiltration: 0.0; percent normal cells: 4.0; percent stromal cells: 35.0; percent tumor cells: 60.0; percent tumor nuclei: 90.0; section location: TOP;